



# Q4/FY | 2021 – PRELIMINARY RESULTS

Investor/Analyst Call  
Dr. Dirk Wössner, CEO  
Michael Rauch, CFO

March 10, 2022

# Disclaimer

The information provided in this presentation pertaining to CompuGroup Medical SE & Co. KGaA (the "Company"), comprise the written materials/slides for presentations or discussions on the occasion of an investor conference, meeting or conference call ("Meeting"). Whilst all reasonable care has been taken to ensure that the information and facts stated herein as well as oral statements made in the Meeting are accurate and that the opinions and expectations contained herein and orally received during the Meeting are fair and reasonable, no representation or warranty, express or implied, is given by or on behalf of the Company, any of its board members, or any other person as to the accuracy or completeness of the information and/or opinions and no liability as to the accuracy of such information and/or opinions is accepted. The information provided in this presentation as well as during the Meeting contain forward looking statements which involve risks and uncertainties. These forward-looking statements speak only as of the date of the documents and are based on numerous assumptions which may or may not prove to be correct. The actual performance and results of the business of the Company could differ materially from the performance and results discussed in this document or in any other information received during the Meeting. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements or other information contained herein or received during the Meeting whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on forward-looking statements or financial projections. The information contained in this presentation and/or received during the Meeting does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto.

# VISION

**NOBODY SHOULD  
SUFFER OR DIE BECAUSE  
AT SOME POINT  
MEDICAL  
INFORMATION WAS  
MISSING**

Frank Gotthardt, Founder



# 2021 - Strong year with acceleration in strategic areas

## Foundation for further growth

Strong execution on investment program

Successful integration of largest two acquisitions in company history



## Delivered progress towards mid term target

>5% organic growth in 2021

Massive step change in digitization in many of our markets

2021

## Focus on company culture

Increasing attention on ESG

Strengthened team spirit after successfully overcoming the cyber attack



## CGM well positioned for the future

# Excellent financial performance in 2021




**More than  
€ 1 billion  
revenue**



**More than  
5 percent  
organic growth**



**Strong adjusted  
EBITDA**



**Growing share  
of recurring  
revenue**

# Great progress towards our mid term ambitions



Organic  
**revenue growth** of  
≥5% per year until 2025

**Delivered 5.8% in 2021,  
targeting 5.5% in 2022**



Increasing  
**EBITDA margin**  
to ~25% in 2023  
and ~27% in 2025

**First step planned  
with 22.5% in 2022**



Increasing **share of  
recurring revenues**  
to >70% in 2025

**Achieved 65% in 2021  
(+2ppt vs last year)**




# Strengthening our excellent market position even further

PLAYER # IN

AI

HS

PCS



## Adding scope and traffic

- New projects with clinical institutions leading in digitization
- ~880k e-sick notes and 1.25m KIM messages processed within CGM network
- MEINE GESUNDHEIT (e-Health record for private insurances) with >1m users
- 80% of US key resellers agree to market CGM's eMEDIX EDI services in the US

# Accelerating organic growth to drive digitization momentum



## AIS (ex US)

Enhancing existing services for physicians with new modules and functionalities, as well as new revenues from patient portals such as CLICKDOC



## US business

After the merger with eMDs – synergistic growth from our strong position revenue cycle management (RCM) and electronic data interchange (EDI)




## HIS business

Market penetration of our G3 platform as well as business from government digitization programs for hospitals



## TI

Expansion of user groups, extension of existing licenses (connector upgrade) and the introduction of additional application modules



## Data


i.e., "Therafox" and real-time evaluation for diagnostics, therapy and medication



# Government programs across Europe continue to push the digitization of essential parts of healthcare


## Strong progress in 2021 to enable healthcare professionals to...

- ... handle e-Health records & e-Prescriptions
- ... digitize medication & emergency data sets
- ... issue electronic sick notes
- ... administer risk assessment for medication
- ... virtualize and mobilize their patient communication
- ... enhance IT security




# 2021: Foundation built for new growth driver data business


**CGM Benchmarking**  
Business Intelligence  
for practices & hospitals



**Therafox**  
Medication safety  
for healthcare professionals



**Medical Decision Support**  
for doctors & hospitals



# ESG in our focus



## We go green

- Develop concept in 2022 to carbon neutrality
- Green projects implemented (TURBOMED, M1 PRO, Romania)
- Customer award for green practices
- Project towards paperless office
- Growing infrastructure of e-car charging stations



## We are more diverse

- New Management Board more international and diverse
- >20% women in leadership positions; 30% by 2023
- Employees of 75 nationalities working @CGM
- German classes for non-German speakers in Germany



## We listen and engage

- New tool to regularly measure employee satisfaction and receive feedback
- Comprehensive online training offering for all employees
- HealthCare@CGM, e.g. vaccination
- Anonymous whistleblowing tool implemented



# Strong and experienced leadership team



**Dr. Dirk Wössner**  
Chief Executive Officer (CEO)



**Frank Brecher**  
Chief Technology Officer (CTO)



**Angela Mazza Teufer**  
Managing Director Ambulatory Information Systems DACH



**Emanuele Mugnani**  
Managing Director Ambulatory Information Systems Europe



**Dr. Eckart Pech**  
Managing Director Consumer and Health Management Information Systems



**Michael Rauch**  
Chief Financial Officer (CFO)



**Hannes Reichl**  
Managing Director Inpatient and Social Care

# CompuGroup Medical 2022 priorities



**Be a top  
player in the  
patient  
journey**



**Deliver great  
services every  
day**



**Innovate on a  
scalable  
platform**



**Be lean and  
reduce  
complexity**



**Lead in data**



**Best place to  
work**



# We are ready to capture this fantastic opportunity!

## **DIGITIZING HEALTHCARE**

**EXCITING MARKET – INNOVATION DRIVEN**

**DEEP INDUSTRY KNOWHOW & MENTALITY TO WIN**

**READY TO TRANSFORM – ECOSYSTEMS EVOLVING**

**CLEAR AMBITION – DRIVING GROWTH & MARGINS**

**ENTREPRENEURIAL SPIRIT – FOUNDER BACKED**

**EXECUTION – FAST, AGILE DECISION MAKING**



# FINANCIALS

Michael Rauch | CFO

# 2021 group guidance fully achieved



**FY**

**€1,025m**  
(+22%yoy)

**65%**  
(+2ppt)

**+5.8%**  
(+1.6ppt)

**€224m**  
(+4%yoy)

**21.9%**  
(-4ppt)

**€1.95**  
(PY: €1.90)

**€101m**  
(PY: €95m)

Revenue

Recurring  
rev share

Organic  
growth

Adj.  
EBITDA

Margin

Adj. EPS

FCF

**Guidance**  
(Feb 4, 2021)



€1,000m-€1,040m



>60%



4-8%



€210m-€230m



20-23%




€1.70-€1.95




>€80m

# Segment guidance overachieved in HIS and CHS








# We are boosting revenue growth to a new level






# CGM now on a new level of sustainable organic growth

Organic growth in % yoy	FY2020	Mid-term ambitions	FY2021
Group	4.2%	>5%	5.8% 
AIS	2%	3 – 6%	4% 
HIS	3%	6 – 8%	8% 
CHS	15%	6 – 9%	10% 
PCS	0%	0 – 2%	1% 

# AIS drives digitization in doctors' practices




## Organic growth picking up in 2021

- Strong organic growth of 4%
- Main drivers: excellent DACH business and progress in France

## Digitization in the European healthcare sector successfully advanced

- More than 100,000 vaccination modules rolled out in Europe
- Communication in medicine (KIM) with ~1,250k messages processed, enabling e-Sick note
- 880,000 e-sick notes processed within the CGM network

# HIS in excellent shape in 2021




## Strong growth and order intake

- 38% revenue growth including acquisitions (Visus, KMS)
- 8% organic growth in 2021
- High profile orders (University clinic Hamburg & Bethel clinic)

## Hospital Future Act

- Project funnel continues to evolve with main areas of care management, patient portal & medication
- Orders of more than € 25 million confirmed
- Revenue impact of € 50 - 80 million expected until 2025

# CHS with great progress in TI and data




## Strong performance in TI in 2021

- TI rollout to pharmacies, strong card reader sales and next generation connector (PTV4+) rollout
- Security products under the new brand CGM Protect launched

## Data business growing 9% in 2021

- CGM BENCHMARKS BI tool subscribed by >3k doctors from 11 specialty groups
- Arznei aktuell app for drug & medication checks; since re-launch >250k registered users
- 8m weekly adverse drug reaction checks in Therafox

# PCS with solid performance and high profitability



## Slight growth and stable margin in 2021

- Revenues slightly up against strong prior year
- Continued strong margin at 29%


## Solid performance in a challenging market environment

- Strong revenue growth in Italian pharmacy business
- German revenue development with tough prior year comps due to Windows 10




# FCF exceeds €100 million in 2021

## Free cash flow



Original guidance 2021: >€80m

## Net debt



Leverage<sup>1)</sup> 2.4x 2.0x 2.8x

# GUIDANCE



# Guidance 2022 delivering on mid-term ambitions

## Our promises for the mid-term published at the CMD 2021

>5% organic revenue  
CAGR 2021-25

>70% recurring  
revenue share in 2025

Increasing adj. EBITDA margin from  
**21.5%** (2021) to **27%** (2025)

## Guidance 2022

5.5% (mid-point)  
organic revenue growth

>65% recurring  
revenue share

**22.5%** adjusted  
EBITDA margin

# Next events 2022










# Q&A

PLEASE PRESS \*1 TO ASK QUESTIONS



# CompuGroup Medical Q4/21

							
<b>Q4</b>	<b>€279m</b> (+15%yoy)	<b>61%</b> (-1ppt)	<b>+2%</b> (-3ppt)	<b>€54m</b> (-10%yoy)	<b>19%</b> (-6ppt)	<b>€0.49</b> (PY: €0.48)	<b>€28m</b> (PY: €15m)
	Revenue	Recurring rev share	Organic growth	Adj. EBITDA	Margin	Adj. EPS	FCF

# Successful investments into further growth

## MILESTONES 2021

- ✓ User experience & platform features  
**CLICKDOC functionalities continuously improving**
- ✓ Modularization & interoperability  
**TI connector rolled out**
- ✓ IT offerings  
**eHealth record module implemented**
- ✓ Next generation G3  
**Successful rollout in AIS Italy**

## 2021

R&D expenses\* up yoy

from **€153m**

to **€203m**

from **18%** to **20%** of revs

\*thereof R&D capex: €38.1m in 2021 and €32.7m in 2020;  
R&D amortization: €15.0m in 2021 and €5.9m in 2020

# In 2021 we delivered on our mid term growth promise

Organic growth in % yoy	Q1	Q2	Q3	Q4	FY
Group	5%	10%	7%	2%	6%
AIS	-1%	3%	10%	7%	4%
HIS	8%	15%	5%	6%	8%
CHS	34%	42%	7%	-13%	10%
PCS	-3%	-1%	3%	5%	1%

# FY/2021 Segments

Group		AIS		HIS		CHS		PCS		
		Revenue share								
	FY/21	yoy	FY/21	yoy	FY/21	yoy	FY/21	yoy	FY/21	yoy
Revenue (€m)	1,025	+22%	476	+27%	257	+38%	174	+10%	118	1%
EBITDA adjusted (€m)	224	+4%	118	+0%	43	+35%	40	-17%	34	+1%
Margin	22%	-4ppt	25%	-6ppt	17%	+0ppt	23%	-8ppt	29%	+0ppt

# Q4/2021 Segment overview

Group		AIS		HIS		CHS		PCS		
		Revenue share								
	Q4/21	yoy	Q4/21	yoy	Q4/21	yoy	Q4/21	yoy	Q4/21	yoy
Revenue (€m)	279	+15%	127	+31%	75	+18%	45	-13%	32	+6%
EBITDA adjusted (€m)	54	-10%	27	-10%	13	-11%	6	-51%	10	+5%
Margin	19%	-6ppt	21%	-10ppt	17%	-6ppt	12%	-9ppt	31%	+0ppt

# AMBULATORY INFORMATION SYSTEMS



# AIS P&L FY/2021

Segment financials		FY/21	yoy
	Revenue (€m)	476	+27%
	EBITDA adjusted (€m)	118	0%
	Margin	25%	-6ppt

76% (+1ppt)

Recurring revenue share



Recurring revenue

## FY/21 yoy

- **Revenues** up +27% due to US acquisition
- **Organic** growth of +4% driven by additional modules and functionalities
- **Recurring revenue** profile now at 76% of total revenues and up +28% yoy
- **Adjusted EBITDA** impacted by growth investments
- **EBITDA margin** additionally impacted by lower margin of newly consolidated US business

# AIS P&L Q4/2021

Segment financials		Q4/21	yoy
	Revenue (€m)	127	+31%
	EBITDA adjusted (€m)	27	-10%
	Margin	21%	-10ppt

75% (+1ppt)

Recurring revenue share



Recurring revenue

## Q4/21 yoy

- **Strong revenue** growth of 31% due to US acquisition
- **Organic growth** of +7%, mostly due to additional modules (eHR, KIM) in DACH region and excellent performance in several European countries (France, Italy and the Nordics)
- **Recurring revenues** up +32%, representing 75% of total revs
- **Adjusted EBITDA** impacted by growth investments
- **EBITDA margin** additionally impacted by lower margin of acquired US business



# HOSPITAL INFORMATION SYSTEMS



CompuGroup  
Medical

# HIS P&L FY/2021

## Segment financials

	FY/21	yoy
Revenue (€m)	257	+38%
EBITDA adjusted (€m)	43	+35%
Margin	17%	+0ppt

64% (+3ppt)

Recurring revenue share



Recurring revenue

## FY/21 yoy

- Strong **revenue** increase of +38% due to acquisitions (Cerner, Visus, KMS)
- **Organic** revenues +8% mainly driven by strong business development in Spain, Germany, Poland and the lab business
- **Recurring revenues** up +47% due to acquisition, representing 64% of total revenue
- **EBITDA margin** stable at 17% despite increasing growth investments

# HIS P&L Q4/2021

## Segment financials

	Q4/21	yoy
Revenue (€m)	75	+18%
EBITDA adjusted (€m)	13	-11%
Margin	17%	-6ppt

60% (+4ppt)

Recurring revenue share



Recurring revenue

## Q4/21 yoy

- Strong **revenue** increase of +18%, including acquisition effects (VISUS & KMS)
- **Organic revenue growth** of +6%, driven by excellent hospital business development in DACH, Poland & Spain and strong performance of lab division
- **Recurring rev share** now at 60%
- **Adjusted EBITDA** impacted by investment program as planned



# CONSUMER & HEALTH MANAGEMENT INFORMATION SYSTEMS





# CHS P&L FY/2021

Segment financials		FY/21	yoy
Revenue (€m)		174	+10%
EBITDA adjusted (€m)		40	-17%
Margin		23%	-8ppt

36% (+2ppt)

Recurring revenue share



Recurring revenue

## FY/21 yoy

- **Outperforming segment guidance**
- **Organic** revenue growth of +10% driven by TI rollout and data solutions
- TI revenues driven by connector upgrade, pharmacy rollout and card reader sales
- **Organic growth ex TI** of +9% due to excellent data business
- **Recurring revenues +14% yoy** due to increased TI base and KIM rollout
- **Adj. EBITDA margin** impacted by continued growth investments into next generation TI, data solutions and increasing investments in consumer

# CHS P&L Q4/2021

Segment financials		Q4/21	yoy
Revenue (€m)		45	-13%
EBITDA adjusted (€m)		6	-51%
Margin		12%	-9ppt

38% (+6ppt)

Recurring revenue share



Recurring  
revenue

## Q4/21 yoy

- **Organic** revenue decrease of -13% yoy as expected due to strong prior year comps in TI (pharmacy rollout in Q4 20)
- **Organic growth ex TI** of +8% due to continued growth in data business
- **Recurring revenue profile** improving mainly due to increasing TI installed base yoy
- **Adjusted EBITDA margin** impacted by growth investments into TI, data and consumer



# PHARMACY INFORMATION SYSTEMS

# PCS P&L FY/2021

## Segment financials

	FY/21	yoy
Revenue (€m)	118	1%
EBITDA adjusted (€m)	34	+1%
Margin	29%	0ppt

66% (+1ppt)

Recurring revenue share



Recurring  
revenue

## FY/21 yoy

- **Revenues** slightly up against strong prior year
- Strong performance in Italy while Germany faced tough prior year comps
- Recurring revenues up +4% and now 66% of total revs
- **Adjusted EBITDA** and margin in line with revenue development

# PCS P&L Q4/2021

## Segment financials

	Q4/21	yoy
Revenue (€m)	32	+6%
EBITDA adjusted (€m)	10	+5%
Margin	31%	0ppt

61% (-1ppt)

Recurring revenue share



Recurring revenue

## Q4/21 yoy

- **Organic** revenues up by 5% mainly due to positive development in Germany and Italy
- Recurring revenues up +4% at 61% of total revs
- **Adjusted EBITDA** up in line with revenue development



# FY/2021 P&L Group

€m	FY/21	FY/20
<b>Revenues</b>	<b>1,025.3</b>	<b>837.3</b>
Capitalized own services /other operating income	62.0	42.4
Expenses for goods & services purchased	-191.4	-156.2
Personnel expenses	-497.7	-377.0
Other operating expenses	-184.8	-149.0
<b>EBITDA reported</b>	<b>213.4</b>	<b>197.5</b>
Depreciation & amortization	-110.7	-75.7
<b>EBIT</b>	<b>102.7</b>	<b>121.8</b>
Financial result	-4.8	-11.4
<b>EBT</b>	<b>97.9</b>	<b>110.4</b>
Income taxes	-28.9	-37.0
<b>Net income</b>	<b>69.0</b>	<b>73.4</b>
Non-controlling interest	0.1	0.2
<b>EPS reported, diluted (€)</b>	<b>1.30</b>	<b>1.40</b>

# Q4/2021 P&L Group

€m	Q4/21	Q4/20
<b>Revenues</b>	<b>279.2</b>	<b>242.9</b>
Capitalized own services /other operating income	27.6	10.1
Expenses for goods & services purchased	-59.3	-54.0
Personnel expenses	-134.6	-100.7
Other operating expenses	-64.1	-50.1
<b>EBITDA reported</b>	<b>48.8</b>	<b>48.2</b>
Depreciation & amortization	-31.9	-23.5
<b>EBIT</b>	<b>16.9</b>	<b>24.7</b>
Financial result	0.2	-5.7
<b>EBT</b>	<b>17.1</b>	<b>19.1</b>
Income taxes	-4.6	-9.6
<b>Net income</b>	<b>12.5</b>	<b>9.5</b>
Non-controlling interest	0.1	0.1
<b>EPS reported, diluted (€)</b>	<b>0.28</b>	<b>0.16</b>

# Adjustment principles for EBITDA and EPS (since January 2020)

- **M&A/Transactions**
  - Financial impact from acquisitions & divestitures of legal entities and/or essential PPE/material assets
  - Amortization/depreciation as well as write-up of investments
  - M&A transaction costs
  - Effects from purchase price allocations (for M&A since Jan 2020 and >€50m transaction volume)
- **Share-based option programs**
  - Accounting impacts of share-based option programs for executive management
- **Restructuring program expenses**
- **Tax impacts on above mentioned adjustment effects**
- **Other non-operative, extraordinary or prior period one-time effects**

# FY/2021 Net income adjustments

€m	FY/21	FY/20
<b>EBITDA adjusted</b>	<b>224.3</b>	<b>214.8</b>
Depreciation & amortization (incl. PPA)	-110.7	-75.7
PPA effects on depreciation & amortization (for M&A since Jan 1, 2020 & >50m transaction volume)	28.6	11.9
<b>EBIT adjusted</b>	<b>142.2</b>	<b>151.1</b>
Financial result	-4.8	-10.2
Income taxes	-34.0	-41.1
<b>Net income adjusted</b>	<b>103.4</b>	<b>99.7</b>
Depreciation & amortization of PPA (for M&A since Jan 1, 2020 & >50m transaction volume)	-28.6	-11.9
M&A related adjustments	-1.8	-10.9
Share-based option programs	-5.7	-5.9
Restructuring expenses	0.0	0.0
Other non-operative, extraordinary or prior period one-time effects	-3.4	-1.8
Taxes attributable to these effects	5.1	4.1
<b>Net income</b>	<b>69.0</b>	<b>73.4</b>

# FY/21 EBITDA bridges to adjusted EBITDA (non-IFRS) and EBIT

€m	FY/21	FY/20
<b>EBITDA reported</b>	<b>213.4</b>	<b>197.5</b>
M&A transactions	1.8	10.9
Share-based option programs	5.7	5.9
Restructuring program expenses	-	-
Other non-operative, extraordinary or prior period one-time effects	3.4	0.6
<b>EBITDA adjusted</b>	<b>224.3</b>	<b>214.9</b>

€m	FY/21	FY/20
<b>EBITDA reported</b>	<b>213.4</b>	<b>197.5</b>
Depreciation & amortization (ex PPA)	-61.8	-44.6
PPA effects on depreciation & amortization	-48.9	-31.1
<i>Thereof PPA adjustments (for M&amp;A since Jan 1, 2020 &amp; &gt;50m transaction volume)</i>	<i>28.6</i>	<i>11.9</i>
<b>EBIT reported</b>	<b>102.7</b>	<b>121.8</b>



# Q4/2021 Net income adjustments

€m	Q4/21	Q4/20
<b>EBITDA adjusted</b>	<b>53.9</b>	<b>59.6</b>
Depreciation & amortization (incl. PPA)	-31.9	-23.4
PPA effects on depreciation & amortization (for M&A since Jan 1, 2020 & >50m transaction volume)	6.4	5.8
<b>EBIT adjusted</b>	<b>28.4</b>	<b>42.0</b>
Financial result	0.2	-5.7
Income taxes	-6.5	-9.9
<b>Net income adjusted</b>	<b>22.1</b>	<b>26.4</b>
Depreciation & amortization of PPA (for M&A since Jan 1, 2020 & >50m transaction volume)	-6.4	-5.8
M&A related adjustments	-0.5	-7.1
Share-based option programs	-1.2	-4.4
Restructuring expenses	-	-
Other non-operative, extraordinary or prior period one-time effects	-3.3	0.1
Taxes attributable to these effects	1.8	0.3
<b>Net income</b>	<b>12.5</b>	<b>9.5</b>

# Q4/21 EBITDA bridges to adjusted EBITDA (non-IFRS) and EBIT

€m	Q4/21	Q4/20
<b>EBITDA reported</b>	<b>48.8</b>	<b>48.2</b>
M&A transactions	0.5	7.1
Share-based option programs	1.2	4.4
Restructuring program expenses	-	-
Other non-operative, extraordinary or prior period one-time effects	3.4	-0.1
<b>EBITDA adjusted</b>	<b>53.9</b>	<b>59.6</b>

€m	Q4/21	Q4/20
<b>EBITDA reported</b>	<b>48.8</b>	<b>48.2</b>
Depreciation & amortization (ex PPA)	-21.1	-12.9
PPA effects on depreciation & amortization	-10.8	-10.6
<i>Thereof PPA adjustments (for M&amp;A since Jan 1, 2020 &amp; &gt;50m transaction volume)</i>	-6.4	-5.8
<b>EBIT reported</b>	<b>16.9</b>	<b>24.7</b>

# Investor Relations contact

## For further information please contact

### **Claudia Thomé**

Corporate Vice President Investor Relations  
T: +49 (0) 160 3630362  
[claudia.thome@cgm.com](mailto:claudia.thome@cgm.com)

### **Frederic Freichel**

Senior Manager Investor Relations  
T: +49 (0) 1703759834  
[frederic.freichel@cgm.com](mailto:frederic.freichel@cgm.com)

### **CompuGroup Medical SE & Co. KGaA**

Maria Trost 21  
56070 Koblenz  
Germany  
E-Mail: [investor@cgm.com](mailto:investor@cgm.com)

ISIN DE000A288904  
WKN A28890  
Frankfurt Stock  
Exchange  
MDAX / TecDAX